Sangamo Therapeutics Inc
SGMO0.540USD
-0.022-3.92%
Market hours （ET）Quotes delayed by 15 min
121.61MMarket Cap
LossP/E TTM
More Details of Sangamo Therapeutics Inc Company
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
Company Info
Ticker SymbolSGMO
Company nameSangamo Therapeutics Inc
IPO dateApr 06, 2000
CEODr. Alexander D. Macrae, Ph.D.
Number of employees183
Security typeOrdinary Share
Fiscal year-endApr 06
Address501 Canal Blvd.
CityRICHMOND
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94084
Phone15109706000
Websitehttps://www.sangamo.com/
Ticker SymbolSGMO
IPO dateApr 06, 2000
CEODr. Alexander D. Macrae, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Scott B. Willoughby
Mr. Scott B. Willoughby
Chief Legal Officer & Corporate Secretary
Chief Legal Officer & Corporate Secretary
350.46K
-8.33%
Ms. Prathyusha Duraibabu, CPA
Ms. Prathyusha Duraibabu, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
344.06K
-8.48%
Dr. Gregory Davis, Ph.D.
Dr. Gregory Davis, Ph.D.
Head of Research & Technology
Head of Research & Technology
205.78K
-3.16%
Ms. Margaret A. Horn, J.D.
Ms. Margaret A. Horn, J.D.
Independent Director
Independent Director
76.40K
+48.64%
Dr. Courtney Beers, Ph.D.
Dr. Courtney Beers, Ph.D.
Independent Director
Independent Director
76.40K
+48.64%
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. John H. Markels, Ph.D.
Dr. John H. Markels, Ph.D.
Independent Director
Independent Director
--
--
Ms. Louise Wilkie
Ms. Louise Wilkie
Investor Relations
Investor Relations
--
--
Ms. H. Stewart Parker
Ms. H. Stewart Parker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Nathalie Dubois- Stringfellow, Ph.D.
Ms. Nathalie Dubois- Stringfellow, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Scott B. Willoughby
Mr. Scott B. Willoughby
Chief Legal Officer & Corporate Secretary
Chief Legal Officer & Corporate Secretary
350.46K
-8.33%
Ms. Prathyusha Duraibabu, CPA
Ms. Prathyusha Duraibabu, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
344.06K
-8.48%
Dr. Gregory Davis, Ph.D.
Dr. Gregory Davis, Ph.D.
Head of Research & Technology
Head of Research & Technology
205.78K
-3.16%
Ms. Margaret A. Horn, J.D.
Ms. Margaret A. Horn, J.D.
Independent Director
Independent Director
76.40K
+48.64%
Dr. Courtney Beers, Ph.D.
Dr. Courtney Beers, Ph.D.
Independent Director
Independent Director
76.40K
+48.64%
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2024
FY2023
No Data
By RegionUSD
Name
Revenue
Proportion
United States
57.80M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
3.95%
Wasatch Global Investors Inc
2.89%
BlackRock Institutional Trust Company, N.A.
1.91%
Biogen Inc
1.37%
Renaissance Technologies LLC
1.33%
Other
88.55%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
3.95%
Wasatch Global Investors Inc
2.89%
BlackRock Institutional Trust Company, N.A.
1.91%
Biogen Inc
1.37%
Renaissance Technologies LLC
1.33%
Other
88.55%
Shareholder Types
Shareholders
Proportion
Investment Advisor
9.68%
Investment Advisor/Hedge Fund
6.21%
Hedge Fund
5.94%
Individual Investor
1.42%
Corporation
1.37%
Research Firm
0.90%
Pension Fund
0.09%
Bank and Trust
0.02%
Other
74.37%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
348
61.31M
25.80%
-60.01M
2025Q1
404
58.78M
24.86%
-65.68M
2024Q4
408
67.57M
32.39%
-54.70M
2024Q3
411
61.90M
29.72%
-75.37M
2024Q2
422
105.29M
52.02%
-52.38M
2024Q1
424
122.66M
61.96%
-20.13M
2023Q4
430
104.60M
58.76%
-36.84M
2023Q3
436
126.62M
71.56%
-23.29M
2023Q2
448
137.28M
80.06%
-15.05M
2023Q1
460
145.31M
88.52%
+4.38M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
9.37M
3.95%
--
--
Mar 31, 2025
Wasatch Global Investors Inc
6.87M
2.89%
-2.36M
-25.59%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.55M
1.91%
+2.82K
+0.06%
Mar 31, 2025
Biogen Inc
3.25M
1.37%
-11.40M
-77.82%
Aug 14, 2024
Renaissance Technologies LLC
3.17M
1.33%
+83.23K
+2.70%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.28M
0.96%
+71.60K
+3.24%
Mar 31, 2025
GSA Capital Partners LLP
966.20K
0.41%
+934.65K
+2962.16%
Mar 31, 2025
Point72 Asset Management, L.P.
2.00M
0.84%
-272.51K
-12.00%
Mar 31, 2025
Ikarian Capital LLC
1.86M
0.78%
--
--
Mar 31, 2025
Susquehanna International Group, LLP
1.81M
0.76%
+1.52M
+535.12%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.52%
iShares Neuroscience and Healthcare ETF
0.32%
Global X Genomics & Biotechnology ETF
0.21%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0%
iShares Micro-Cap ETF
0%
ProShares Hedge Replication ETF
0%
Schwab U.S. Small-Cap ETF
0%
SPDR S&P Kensho New Economies Composite ETF
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.52%
iShares Neuroscience and Healthcare ETF
Proportion0.32%
Global X Genomics & Biotechnology ETF
Proportion0.21%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Fidelity Enhanced Small Cap ETF
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
SPDR S&P Kensho New Economies Composite ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
